Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose Chemotherapy with Autologous HSCT for TNBC
NCT02670109Phase 2Unknown
- Sponsor
- Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
- Start
- Feb 2018
- Primary completion
- Nov 2020
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of carmustine, cyclophosphamide, carboplatin, busulfan in triple-negative breast cancer (TNBC), sponsored by Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Status: unknown.
02
Drugs
carmustinecyclophosphamidecarboplatinbusulfan
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02670109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02670109.